Master Protocols-including platform, umbrella, and basket trials-offer significant benefits and efficiencies in drug development compared with traditional trial protocols. However, their perpetual nature, adaptive designs, and evolving requirements make randomisation inherently more complex. As a result, implementing and maintaining robust randomisation for Master Protocols can be challenging for sponsors. Selecting the right IRT provider is therefore critical. This paper outlines five essential questions sponsors should ask when evaluating IRT providers for Master Protocols, with a focus on long-term trial success, regulatory readiness, and operational resilience.
Date:
More like thisRelated
RISK MANAGEMENT FROM RISK CONTROL TO GROWTH ENGINE
As organisations navigate an increasingly complex landscape shaped by...
60% of AU and SG brands missed their moment last year.
Klaviyo surveyed 400+ B2C marketers across Australia and Singapore...
AI hasn’t created “the AI shopper.” It’s created four.
Most brands are making a costly assumption: that their...
What is discounting actually costing ANZ brands?
ew research from marketing effectiveness expert James Hurman across...